Table III.

Recognition of peptide and tumor before and after immunization: ELISPOT assay

Patient	Pre							After Three or Four Courses
	CIRA2 + peptide			Melanoma				CIRA2 + peptide			Melanoma
	0	280	209	526	624	888	938	0	280	209	526	624	888	938
				(A2⁺)	(A2⁺)	(A2⁻)	(A2⁻)				(A2⁺)	(A2⁺)	(A2⁻)	(A2⁻)
	(Number spots/10⁵ PBMC)
1	24	24	28	7	10	6	10	10	8	290 ^a	41	41	5	7
2	10	8	11	7	11	5	1	7	3	321	22	29	5	8
3	26	17	26	8	10	5	1	25	18	1160	432	227	15	93
4	21	17	25	79	152	75	26	10	10	266	220	300	161	63
5	12	7	8	9	3	7	3	8	8	509	3	4	0	4
6	33	30	47	17	5	5	9	52	24	489	89	37	7	44
7	84	62	79	211	24	18	24	13	15	577	284	117	11	150
8	24	9	23	14	20	5	8	5	3	507	97	34	0	69
9	35	22	17	5	30	6	8	2	0	710	42	17	0	24
10	16	15	11	12	14	16	5	67	48	636	105	36	19	67
11	5	5	5	9	11	12	4	15	10	782	299	334	30	15
12	12	11	18	11	14	18	11	11	13	725	88	143	11	7
13	13	10	13	13	13	18	4	29	20	1486	219	234	50	38
14	5	5	5	8	17	20	11	2	3	377	56	52	31	16
15	13	9	9	6	8	20	10	13	4	1474	613	574	25	24
16	20	16	20	20	21	32	35	33	15	2082	627	773	43	39
17	8	9	10	11	31	20	18	6	3	831	113	165	28	23

a Values twice both controls are underlined.